MARKET

KLRA

KLRA

Kailera Therapeutics
NASDAQ
16.21
-2.32
-12.52%
After Hours: 16.43 +0.22 +1.36% 19:52 08/28 EDT
OPEN
18.26
PREV CLOSE
18.53
HIGH
18.26
LOW
16.19
VOLUME
532.03K
TURNOVER
--
52 WEEK HIGH
28.23
52 WEEK LOW
16.19
MARKET CAP
2.10B
P/E (TTM)
-9.3889
1D
5D
1M
3M
1Y
5Y
1D
THQ Offers High-Yield Income From Healthcare Stocks (Rating Upgrade)
Seeking Alpha · 1d ago
Weekly Report: what happened at KLRA last week (0817-0821)?
Weekly Report · 5d ago
Weekly Report: what happened at KLRA last week (0810-0814)?
Weekly Report · 08/17 10:41
2 GLP-1 Stocks That Could Double Your Money by 2031
NASDAQ · 08/16 20:20
Analysts Offer Insights on Healthcare Companies: Medicus Pharma Ltd (MDCX) and Kailera Therapeutics, Inc. (KLRA)
TipRanks · 08/14 14:50
Analyst Initiates Buy on Kailera, Citing Differentiated Obesity Pipeline and DCF-Based $30 Price Target
TipRanks · 08/13 14:37
Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA), Warby Parker (WRBY) and Aprea Therapeutics (APRE)
TipRanks · 08/13 11:50
Analysts’ Opinions Are Mixed on These Healthcare Stocks: P3 Health Partners (PIII) and Kailera Therapeutics, Inc. (KLRA)
TipRanks · 08/13 00:10
More
About KLRA
Kailera Therapeutics, Inc. is a clinical-stage biotechnology company focused on obesity care. The Company is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for weight loss. Ribupatide injection is in global Phase III trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. The Company is developing a once-daily oral tablet formulation, ribupatide oral, to provide a convenient oral option with compelling weight loss among oral treatments. Additionally, it is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist.

Webull offers Kailera Therapeutics Inc stock information, including NASDAQ: KLRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KLRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KLRA stock methods without spending real money on the virtual paper trading platform.